Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial
- EClinicalMedicine, November 13, 2025 | https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00580-2